Schering-Plough expands into two Rx franchises with acquisition of Organon

By Lisa Kerner

Charlotte, N.C., Nov. 19 - Schering-Plough Corp. completed its $14.4 billion acquisition of Organon BioSciences NV from Akzo Novel NV, the company announced on Monday.

Organon includes a human health business; Intervet, an animal health business; Nobilon, a human vaccine development unit; and Diosynth, a third-party manufacturing unit.

"Through this combination we create a powerful science and technology platform. We expand and strengthen Schering-Plough's late-stage Rx pipeline with five additional promising phase 3 compounds," chairman and chief executive officer Fred Hassan said in a company news release.

In addition, the acquisition allows Schering-Plough to expand into what it considers two important prescription pharmaceutical franchises: women's health and central nervous system.

Schering-Plough begins a leader in animal health with the addition of Intervet to Schering-Plough Animal Health.

Schering-Plough is a science-based health care company based in Kenilworth, N.J.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.